Chemical engineering grad previously headed gene therapy manufacturing for Novartis

Biologics manufacturing expert Andrew Stober '93, a chemical engineering alum, was recently named chief manufacturing officer for Encoded Therapeutics Inc., a biotechnology company specializing in the development of precision gene therapy for a range of severe genetic disorders. 

"There has never been a more exciting time in gene therapy than now," says Stober. "I am thrilled at the opportunity to leverage my experience in gene therapy manufacturing to support Encoded's innovative platform and make manufacturing a core capability of the company."

Stober is a veteran in the biotech industry. Over the past 20 years, he’s held senior leadership roles at firms including AveXis, Biogen, Amgen, and Merck & Co. In his most recent role, he led gene therapy manufacturing at Novartis, where he significantly expanded capacity, sought cost-effective solutions, and made gene therapy manufacturing a company strength.

Encoded, which is based in South San Francisco, seeks to overcome key limitations of viral gene therapy and develop innovations that move away from disease management and toward lasting disease modification. 

Stober will lead strategic development to support the global needs of the company’s gene therapy pipeline.

Andrew Stober

Chemical engineering alum Andrew Stober '93 was recently appointed chief manufacturing officer for biotech company Encoded Therapeutics. Credit: Encoded Therapeutics